Recombinant Vaccines Market

  • Published on 2025-11-10
  • Report Code: 304
  • 174 pages
Recombinant Vaccines Market

COVID-19 Impact on Global Recombinant Vaccines Market By Patient Type (Pediatric and Adult Patients); By Technology (Conjugate Vaccines, Inactivated And Subunit Vaccines, Live Attenuated Vaccines, Recombinant Vaccines and Toxoid Vaccines) and Region -Analysis of Market Size, Share and Trends for 2014 - 2019 and Forecasts to 2030

Table Of Content

Contents        

  1. Executive Summary
  2. Recombinant Vaccines Market
    1. Product Overview
    2. Market Definition
    3. Segmentation
    4. Assumptions and Acronyms
  3. Research Methodology
    1. Research Objectives
    2. Primary Research
    3. Secondary Research
    4. Forecast Model
    5. Market Size Estimation
  4. Average Pricing Analysis
  5. Market Dynamics
    1. Growth Drivers
    2. Restraints
    3. Opportunity
    4. Trends
  6. Correlation & Regression Analysis
    1. Correlation Matrix
    2. Regression Matrix
  7. Recent Development, Policies & Regulatory Landscape
  8. Risk Analysis
    1. Demand Risk Analysis
    2. Supply Risk Analysis
  9. Recombinant Vaccines Market Analysis
    1. Porters Five Forces
      1. Threat of New Entrants
      2. Bargaining Power of Suppliers
      3. Threat of Substitutes
      4. Rivalry
    2. PEST Analysis
      1. Political
      2. Economic
      3. Social
      4. Technological
  10. Recombinant Vaccines Market
    1. Market Size & forecast, 2019A-2030F
      1. By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
      2. By Volume (Million Units) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
  11. Recombinant Vaccines Market: Market Segmentation
    1.       By Regions
      1. North America:(U.S. and Canada)
        • By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
      2. Latin America: (Brazil, Mexico, Argentina, Rest of Latin America)
        • By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
      3. Europe: (Germany, UK, France, Italy, Spain, BENELUX, NORDIC, Hungary, Poland, Turkey, Russia, Rest of Europe)
        • By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
      4. Asia-Pacific: (China, India, Japan, South Korea, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia Pacific)
        • By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
      5. Middle East and Africa: (Israel, GCC, North Africa, South Africa, Rest of Middle East and Africa)
        • By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
  12. Recombinant Vaccines Market: Market Segmentation
    1. By technology: Market Share (2020-2030F)
      1. conjugate vaccines, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
      2. inactivated and subunit vaccines, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
      3. live attenuated vaccines, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
      4. recombinant vaccines, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
      5. toxoid vaccines, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
    2. By patient type : Market Share (2020-2030F)
      1. pediatric, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
      2. adult patients, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
  13. Company Profile
    1. Johnson and Johnson
      1. Company Overview
      2.  Company Total Revenue (Financials)
      3.  Market Potential
      4. Global Presence
      5.  Key Performance Indicators
      6. SWOT Analysis
      7. Product Launch
    2. Abiomed
    3. Emergent Bio Solutions, Inc.
    4. GlaxoSmithKline
    5. Sanofi Pasteur SA
    6. Serum Institute of India Pvt. Ltd
    7. Mitsubishi Tanabe Pharma Corporation
    8. Daiichi Sankyo
    9. Pfizer, Inc.
    10. Other prominent players
  14. Consultant Recommendation

**The above-given segmentation and companies could be subjected to further modification based on in-depth feasibility studies conducted for the final deliverable.

To request a free sample copy of this report, please complete the form below.

Select License Type

$ 4950

Report accessible by 1 user only

In case you require a hard copy, there will be an additional charge of $500. Please email us at [email protected] with your request.

Read all reports

Our Clients

We have been working with some Fortune 500+ clients